Prof Hassan Abolhassani
—
Altogether 414 papers published in the areas of primary immunodeficiencies, clinical immunology, immunotherapy, and immunoepidemiology. First author for 45 papers and senior or shared senior author for 72 papers. Average impact factor of top papers 88.5 106 papers in high impact journals (impact factor >10). Total citations and H index: 72032 and 88. One edited Textbook and eleven additional book chapters. Major scientific achievements 1. Identification of novel disease-causing genes or regulatory molecules involved in antibody deficiency, including LRBA, RAC2, CD27, CD70, BARD1, BAP1, APOBEC2. 2. Multidisciplinary and translational approaches for diagnosis and treatment of Ataxia Telangectasia. 3. Contributed to the identification of the genetic and immunological basis of severe cases of COVID-19 (IFNAR1, TLR7; autoantibodies against type I IFN). 4. Characterization of the disease associated with iVDPV and advisor of Polio Eradication Initiative and WHO projects on primary immunodeficiencies. 5. Identification of burden of immune related diseases in collaboration with Global Burden of Disease. 6. Establishment of Middle East and North Africa Registry on Inborn Errors of Immunity (MENA-IEI), one of the largest PID cohorts worldwide (more than 17000-patients) performing translational research on immune defects and specific PID with B cell defects and immune dysregulation